Pliant Therapeutics Quote, Financials, Valuation and Earnings

Pliant Therapeutics Price Quote

-0.03 (-0.34%)
(Updated: March 24, 2023 at 5:24 AM ET)

Pliant Therapeutics Key Stats

Pliant Therapeutics (PLRX) is a Sell

Day range:
$25.63 - $26.67
52-week range:
$3.97 - $36.64
Dividend yield:
P/E ratio:
P/S ratio:
P/B ratio:

Avg. volume:
1-year change:
Market cap:

How Much Does Pliant Therapeutics Make?

Is Pliant Therapeutics Growing As A Company?

  • What Is Pliant Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.02%
  • What Is Pliant Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Pliant Therapeutics Stock Price Performance

What Is Pliant Therapeutics 52-Week High & Low?

Pliant Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Pliant Therapeutics?

Is Pliant Therapeutics Cash Flow Positive?

  • What Is PLRX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$94.6M
  • What Is Pliant Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $226.9M
  • What Is Pliant Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$150.2M

Pliant Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    PLRX return on invested capital is -51.36%
  • What Is Pliant Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -46.34%
  • What Is PLRX Return On Equity?
    ROE is a measure of profitability and is -52.66%

Pliant Therapeutics Earnings Date & Stock Price

Pliant Therapeutics Competitors

  • Who Are Pliant Therapeutics's Competitors?
    Below is a list of companies who compete with Pliant Therapeutics or are related in some way:
    • Avalo Therapeutics Inc (AVTX)
    • Catalyst Pharmaceuticals Inc (CPRX)
    • Intelligent Bio Solutions Inc (INBS)
    • Protalix BioTherapeutics Inc (PLX)
    • RenovoRx Inc (RNXT)

Pliant Therapeutics Dividend Yield

Data Unavailable

Pliant Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -2.86%
Revenue: -1.7% 62.25%

Analyst Recommendations

Buy Recommendations: 7
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 48.27
Upside from Last Price: 85.31%

Major Shareholders

  • How many PLRX shares are owned by institutional investors?
    66.6M PLRX shares are owned by institutional investors
  • How many PLRX shares are owned by insiders?
    708.1K PLRX shares are owned by insiders